Seres Therapeutics (MCRB) Tops Q4 EPS by 9c

Seres Therapeutics (NASDAQ: MCRB) reported Q4 EPS of ($0.63), $0.09 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $3 million versus the consensus estimate of $2.85 million.

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• KeyBanc Upgrades Nucor (NUE) to Overweight
• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI